Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy that
can involve the bone marrow, peripheral blood, skin, lymph nodes, and the central nervous …

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and clinically challenging
hematologic malignancy with dismal outcomes. With a median age of∼ 70 years, the …

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized
by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other …

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia for
which we developed a nationwide network to collect data from new cases diagnosed in …

Myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) are
reported in up to 20% patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) …

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy
with historically poor outcomes and no worldwide consensus treatment approach. Unique …

The purpose of this study is to describe the clinical and prognostic features and to evaluate
the outcome of different therapeutic approaches among patients with blastic plasmacytoid …

Abstract Purpose of Review Immunohistochemistry is an integral technique for tissue-based
diagnostics and biomarker detection with broad worldwide adoption. Advances in core …

Oncogenesis and ontogeny of blastic plasmacytoid dendritic cell neoplasm (BPDCN) remain
uncertain, between canonical plasmacytoid dendritic cells (pDCs) and AXL+ SIGLEC6+ DCs …

Abstract Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is an aggressive
hematological malignancy; however, some patients achieve durable remission with …